Patents Represented by Attorney J. Scott Young

Find this attorney in the Justia Lawyer Directory

  • 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoMethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2 as NK1 receptor antagonists
    Patent number: 8344005
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is C1-4 alkyl useful in the treatment of diseases and conditions for which antagonism of NK1 receptor is beneficial.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: January 1, 2013
    Assignee: Glaxo Wellcome Manufacturing Pte Ltd
    Inventors: Giuseppe Alvaro, Agostino Marasco
  • Anhydrous crystal form of ovrepitant maleate
    Patent number: 8309553
    Abstract: The invention relates to anhydrous crystalline orvepitant maleate (Form 1), pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same, wherein orvepitant is as shown in formula (I).
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: November 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Stefania Beato, Franco Sartor, Ian Philip Steeples
  • Process for preparing N, N-substituted carbamoyl halides
    Patent number: 8188290
    Abstract: The present invention relates to a new and useful process for preparing N,N-substituted carbamoyl halides from secondary amines, carbon dioxide, trialkylsilyl chloride and a halogenating agent.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 29, 2012
    Assignee: Glaxo Group Limited
    Inventors: Ilaria Bientinesi, Zadeo Cimarosti, Giuseppe Guercio, Corinne Leroi, Alcide Perboni
  • Pyridine derivatives and their use in the treatment of psychotic disorders
    Patent number: 8097618
    Abstract: A method of treatment of anxiety disorders which comprises administering to a host in need thereof an effective amount of a compound of formula (I):
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: January 17, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • Imidazopyridine kinase inhibitors
    Patent number: 8093239
    Abstract: The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: January 10, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Kevin Kuntz, David Edward Uehling, Alex Gregory Waterson, Kyle Allen Emmitte, Kirk Stevens, John Brad Shotwell, Stephon Cornell Smith, Kristen E. Nailor, James M. Salovich, Brian John Wilson, Mui Cheung, Robert Anthony Mook, Erich W. Baum, Ganesh Moorthy
  • Crystalline forms of a pyridine derivative
    Patent number: 8093242
    Abstract: The invention relates to 4-methylbenzenesulfonate salt of the compound of formula (I) in a crystalline form or a solvate thereof, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: January 10, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Clare Louise Anderton, Ronnie Maxwell Lawrence, David Clapham
  • Benzene sulfonamide thiazole and oxazole compounds
    Patent number: 7994185
    Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: August 9, 2011
    Assignee: Glaxo Smith Kline LLC
    Inventor: Tara Renae Rheault
  • 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
    Patent number: 7981903
    Abstract: Novel pyrrolopyrimidines as shown in formula (I): and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Stanley Dawes Chamberlain, Felix Deanda, Jr., Roseanne Gerding, Masaichi Hasegawa, Kevin Kuntz, Huangshu Lei, Yasushi Miyazaki, Naohiko Nishigaki, Samarjit Patnaik, Aniko Redman, John Brad Shotwell, Kirk Stevens, Joseph Wilson, Bin Yang
  • Indazoles used to treat estrogen receptor beta mediated disorders
    Patent number: 7960563
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 14, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Compounds
    Patent number: 7956083
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 7, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • Pyridine derivatives and their use in the treatment of psychotic disorders
    Patent number: 7919491
    Abstract: A pyridine derivative novel compounds of formula (I) or a pharmaceutically acceptable salt thereof where all variables are defined herein. The compounds are useful in the treatment of psychotic disorders.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: April 5, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • Treatment of cancers expressing p95 ErbB2
    Patent number: 7829297
    Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: November 9, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Neil Lee Spector, Wenle Xia
  • 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
    Patent number: 7812022
    Abstract: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: October 12, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Edward Uehling, Kirk Lawrence Stevens, Scott Howard Dickerson, Alex Gregory Waterson, Philip Anthony Harris, Douglas McCord Sammond, Robert Dale Hubbard, Holly Kathleen Emerson, Joseph W. Wilson
  • 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
    Patent number: 7807673
    Abstract: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: October 5, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Edward Uehling, Robert Dale Hubbard, Alex Gregory Waterson, Kimberly Petrov, Neil Bifulco, Jr., Joseph Wendell Wilson, Jennifer Gabriel Badiang, Mul Cheung, Mariko Yamabe
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7799828
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: September 21, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Predictive biomarkers in cancer therapy
    Patent number: 7794960
    Abstract: The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: September 14, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Neil Lee Spector, Albert Man
  • Cycloalkylidene compounds as selective estrogen receptor modulators
    Patent number: 7723393
    Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 25, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
  • Pyridine derivatives and their use in the treatment of psychotic disorders
    Patent number: 7683056
    Abstract: There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein all variables are defined herein. Also provided are pharmaceutical compositions containing the same and methods for their use in therapy.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 23, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Sandro Belvedere
  • 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof
    Patent number: 7652012
    Abstract: The present invention relates to piperidine derivatives of formula (I) specifically 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide maleate and pharmaceutical compositions thereof, useful in the treatment of conditions mediated by tachykinins.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: January 26, 2010
    Assignee: Glaxo Group Limited
    Inventors: Giuseppe Alvaro, Romano Di Fabio, Maria Elvira Tranquillini, Simone Spada
  • Naphthalene compounds as selective estrogen receptor modulators
    Patent number: 7649093
    Abstract: The present invention relates to cycloalkylidene compounds with a variety of therapeutic uses, more particularly novel naphthalene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: January 19, 2010
    Assignee: Glaxo Smith Kline LLC
    Inventors: Dennis Heyer, Jing Fang, Frank Navas, III, Subba Reddy Katamreddy, Jennifer Poole Peckham, Philip Stewart Turnbull, Aaron Bayne Miller, Adwoa Akwabi-Ameyaw